Abstract: Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The therapeutic effect is achieved via inhibition of viral neuraminidases, also known as viral sialidases. These neuraminidases are classified under the GH34 family of viral enzymes.

Abstract: A wall repair apparatus, system, and method to repair localized wall damage and easily support an installed wall repair patch are disclosed. The disclosed embodiments provide a convenient way to both position and align a wall repair patch with the outer face of the wall surface and support it in place from within the wall cavity. The wall repair apparatus supports and reinforces a wall repair patch to prevent the wall repair patch from moving within a repaired wall, thus causing further damage. The wall repair apparatus comprises a female interlocking member and a male interlocking member that are appropriately sized to securely fit inside of a wall cavity, behind a wall repair patch. A male interlocking member with annular rings is sized to fit within a female interlocking member to form a tension-fitted wall repair apparatus that spans a wall cavity and supports a wall repair patch.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: Particular naturally occurring glycosylated acyl-flavonols are now shown to be effective mammalian ?-amylase inhibitors. Such compounds can be obtained from plants of the genus Crocosmia and the compounds are useful in controlling starch digestion such as for management of glycemia in pre-diabetic or diabetic subjects, for management of obesity or for inhibiting oral caries or plaque formation.

Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.

Abstract: Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The therapeutic effect is achieved via inhibition of viral neuraminidases, also known as viral sialidases. These neuraminidases are classified under the GH34 family of viral enzymes.

Abstract: A wall repair apparatus, system, and method to repair localized wall damage and easily support an installed wall repair patch are disclosed. The disclosed embodiments provide a convenient way to both position and align a wall repair patch with the outer face of the wall surface and support it in place from within the wall cavity. The wall repair apparatus supports and reinforces a wall repair patch to prevent the wall repair patch from moving within a repaired wall, thus causing further damage. The wall repair apparatus comprises a female interlocking member and a male interlocking member that are appropriately sized to securely fit inside of a wall cavity, behind a wall repair patch. A male interlocking member with annular rings is sized to fit within a female interlocking member to form a tension-fitted wall repair apparatus that spans a wall cavity and supports a wall repair patch.

Abstract: Particular naturally occurring glycosylated acyl-flavonols, e.g.

Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Abstract: The invention provides a method for treating an animal suffering from a disease associated with reduced activity of a lysosomal hexosaminidase by administering to the animal an effective amount of a compound which increases the activity of the hexosaminidase.

Abstract: Mutant glycosidases in which the amino acid in the active site that serves as the acid, base or acid/base-catalyst is converted from a carboxylic acid to some other amino acid (for example to a simple alkyl, as in alanine or glycine) can catalyze the reaction of a thiosugar acceptor and an activated donor to form a thioglycoside. The “thioglycoligases” represent a novel class of mutant enzymes, and represent a first aspect of the invention. Thioglycoligases can be used in accordance with the method of the invention to couple a thiosugar acceptor and an activated donor to form a thioglycoside. By selection of the donor and acceptor species, as well as the specific enzyme employed, thioglycosides of different structure and stereochemistry can be obtained.

Abstract: Mutant glycosidases in which the amino acid in the active site that serves as the acid, base or acid/base-catalyst is converted from a carboxylic acid to some other amino acid (for example to a simple alkyl, as in alanine or glycine) can catalyze the reaction of a thiosugar acceptor and an activated donor to form a thioglycoside. The “thioglycoligases” represent a novel class of mutant enzymes, and represent a first aspect of the invention. Thioglycoligases can be used in accordance with the method of the invention to couple a thiosugar acceptor and an activated donor to form a thioglycoside. By selection of the donor and acceptor species, as well as the specific enzyme employed, thioglycosides of different structure and stereochemistry can be obtained.